This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen Idec And Eisai Announce Manufacturing Alliance At Research Triangle Park Facilities

Biogen Idec (NASDAQ: BIIB) and Eisai Inc. today announced a strategic alliance that will bolster the manufacturing capabilities of both companies’ Research Triangle Park (RTP)-based facilities. Under the terms of the agreement, Biogen Idec will lease a portion of the Eisai facility to manufacture oral solid dose products for both companies. Eisai will provide Biogen Idec with vial-filling services for biologic therapies and packaging services for oral solid dose products. The 10-year lease agreement gives Biogen Idec the option to purchase the Eisai oral solid dose facility.

“We view our supply chain as a lifeline to patients, designed to deliver quality therapies wherever and whenever they are needed,” said John G. Cox, executive vice president of Pharmaceutical Operations and Technology, for Biogen Idec. “This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics.”

Approximately 50 Eisai personnel are expected to become Biogen Idec employees in early 2013, building on the company’s RTP workforce which exceeded 1,000 in 2012. Eisai currently employs approximately 225 full-time employees at its RTP site.

"We look forward to collaborating with Biogen Idec to continue the proud history of drug manufacturing excellence here at our RTP site," said Lou Arp, general manager of the Eisai RTP site and president of Global Oncology Manufacturing, for Eisai Inc. "Our alliance will enable both companies to focus on respective areas of expertise while continuing to deliver high-quality and innovative products to patients. Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers.”

Biogen Idec and Eisai have both operated manufacturing facilities in RTP since the mid-1990s. “This alliance underscores the Triangle region’s reputation as a globally competitive location for life sciences,” said Bob Geolas, president and CEO of the Research Triangle Foundation. “In addition, it’s an illustration of the type of collaboration we encourage and foresee becoming more commonplace as the Park moves forward with its new Master Plan.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs